These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34634625)

  • 1. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder.
    Thakolwiboon S; Zhao-Fleming H; Karukote A; Mao-Draayer Y; Flanagan EP; Avila M
    Mult Scler Relat Disord; 2021 Nov; 56():103310. PubMed ID: 34634625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
    Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
    Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
    J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.
    Wang X; Kong L; Zhao Z; Shi Z; Chen H; Lang Y; Lin X; Du Q; Zhou H
    Front Immunol; 2022; 13():953993. PubMed ID: 35958613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis.
    Lai QL; Zhang YX; Cai MT; Zheng Y; Qiao S; Fang GL; Shen CH
    Ther Adv Neurol Disord; 2021; 14():17562864211054157. PubMed ID: 34790259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
    Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
    J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
    Pizzolato Umeton R; Waltz M; Aaen GS; Benson L; Gorman M; Goyal M; Graves JS; Harris Y; Krupp L; Lotze TE; Shukla NM; Mar S; Ness J; Rensel M; Schreiner T; Tillema JM; Roalstad S; Rodriguez M; Rose J; Waubant E; Weinstock-Guttman B; Casper C; Chitnis T;
    Neurology; 2023 Feb; 100(9):e985-e994. PubMed ID: 36460473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
    Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
    BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis.
    Magdalena C; Clarissa A; Sutandi N
    Innov Clin Neurosci; 2022; 19(4-6):51-64. PubMed ID: 35958974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
    Chen JJ; Flanagan EP; Bhatti MT; Jitprapaikulsan J; Dubey D; Lopez Chiriboga ASS; Fryer JP; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Lucchinetti CF; Kunchok A; McClelland CM; Lee MS; Bennett JL; Pelak VS; Van Stavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Lam BL; Moss H; Beres S; Gilbert AL; Shah V; Armstrong G; Heidary G; Cestari DM; Stiebel-Kalish H; Pittock SJ
    Neurology; 2020 Jul; 95(2):e111-e120. PubMed ID: 32554760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
    Dong GY; Meng YH; Xiao XJ
    Medicine (Baltimore); 2022 Sep; 101(36):e30347. PubMed ID: 36086713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
    Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.